"The White House rolled out a plan this weekend to contain political damage from the administration's response to Hurricane Katrina," reports the New York Times.
Merck's PR campaign around the Vioxx recall includes "three full-page ads in seven prominent newspapers," "several television appearances," and "testimony before Congress by the company's chief executive." But the president of a New York crisis-management firm says, "They really need some third-party endorsements
U.S. Food and Drug Administration reviewer David Graham told Congress that "at least five medications now sold to consumers pose such risks that their sale should be limited or stopped." They are the weight-loss drug Meridia, anti-cholesterol drug Crestor, acne drug Accutane, painkiller Bextra and asthma treatment Serevent.
Wal-Mart CEO H. Lee Scott recently said, "We have not gotten our story out to the extent that we need to." The head of the global super store told a retailing conference that Wal-Mart's bad reputation came from newspapers and television. But a New York Times editorial responded that "if Wal-Mart wants to improve its image, it should focus less on shaping its message and more on changing the way it does business. ... These damaging news stories are not a product of bad spin, but bad facts.
"Worried that county bans on biotech crops could spread throughout the state, mainstream farm groups from the California Cattlemen's Association to the national Farm Bureau are marshaling their resources," reports the Sacramento Bee.
"Stung by criticism of its labor practices, expansion plans and other business tactics," Wal-Mart "has become a sponsor on National Public Radio," underwritten the "Tavis Smiley" talk show, and "plans to award $500,000 in scholarships to minority students at journalism programs around the country." A Wal-Mart spokeswoman said there's "no hidden agenda," but "we've really been in the spotlight and I think t
"It's amazing how far the reputation of electronic voting has fallen," writes Center for Media and Democracy researcher Diane Farsetta.
Just 13 percent of Americans think pharmaceutical companies are "generally honest and trustworthy," according to a recent survey.